本次会计政策变更后，公司将按照财政部发布的《准则解释第17号》的相 关规定执行。除上述政策变更外，其他未变更部分，仍按照财政部前期颁布的 《企业会计准则—基本准则》和各项具体会计准则、企业会计准则应用指南、 企业会计准则解释公告以及其他相关规定执行。 监事会认为：本次会计政策变更是公司根据财政部的相关文件要求进行的 合理变更，执行会计政策变更能够更加客观、公允地反映公司的财务状况和经 营成果。本次会计政策变更的决策程序符合有关法律、法规和《公司章程》的 规定，不存在损害公司及全体股东特别是中小股东的利益的情形。 重庆正川医药包装材料股份有限公司监事会 重庆正川医药包装材料股份有限公司监事会 关于会计政策变更的意见 2023 年 10 月 25 日，财政部发布了《企业会计准则解释第 17 号》（财会 〔2023〕21 号）（以下简称"《准则解释第 17 号》"）。《准则解释第 17 号》规定， "关于流动负债与非流动负债的划分"、"关于供应商融资安排的披露"和"关于 售后租回交易的会计处理"内容自 2024 年 1 月 1 日起施行。 根据《准则解释第17号》的要求，本次会计政策变更主要涉及关于流动负 债与非流 ...

重庆正川医药包装材料股份有限公司董事会 重庆正川医药包装材料股份有限公司董事会 2024 年 4 月 26 日 关于 2023 年度独立董事独立性情况的专项意见 根据中国证监会《上市公司独立董事管理办法》《上市公司自律监管指引第 1 号--规范运作》的规定，独立董事应当每年对任职独立性进行自查，并将自 查情况提交董事会。董事会应当每年对在任独立董事独立性情况进行评估并出 具专项意见。基于此，董事会就公司在任独立董事的独立性情况进行评估并出 具如下专项意见： 经核查独立董事徐细雄、盘莉红、胡文言的任职经历以及签署的相关自查 文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨 碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董事 管理办法》《上海证券交易所上市公司自律监管指引第 1 号--规范运作》中对 独立董事独立性的相关要求。 ...

Financial Performance - The company's operating revenue for Q1 2024 was CNY 245,711,123.16, representing an increase of 8.94% compared to the same period last year[5]. - Net profit attributable to shareholders of the listed company reached CNY 21,047,590.27, marking a significant increase of 61.97% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 20,382,258.79, reflecting an increase of 88.37% compared to the previous year[5]. - The basic earnings per share (EPS) was CNY 0.14, which is a 55.56% increase from the same period last year[5]. - Total operating revenue for Q1 2024 reached ¥245,711,123.16, an increase of 8.5% compared to ¥225,554,847.36 in Q1 2023[16]. - Net profit for Q1 2024 was ¥21,047,590.27, representing a significant increase of 62.1% from ¥12,994,745.54 in Q1 2023[17]. - Earnings per share for Q1 2024 were ¥0.14, compared to ¥0.09 in Q1 2023, indicating a 55.6% increase[18]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,060,517,499.20, showing a slight increase of 0.86% from the end of the previous year[6]. - As of March 31, 2024, total assets amounted to RMB 2,060,517,499.20, an increase from RMB 2,042,882,148.49 as of December 31, 2023, reflecting a growth of approximately 0.86%[12]. - Current assets totaled RMB 1,082,702,774.69, up from RMB 1,051,164,929.37, indicating an increase of about 3.9%[13]. - Total liabilities decreased slightly to RMB 823,952,983.77 from RMB 827,365,223.33, a reduction of approximately 0.5%[14]. - The company's equity remained stable at RMB 1,236,564,515.43, consistent with the previous period[14]. Cash Flow - The net cash flow from operating activities was CNY 4,617,978.95, which represents a decrease of 88.23% compared to the same period last year[5]. - Cash flow from operating activities for Q1 2024 was ¥4,617,978.95, a decrease of 88.2% from ¥39,221,086.61 in Q1 2023[21]. - The net cash increase for the period was 19,872,078.32, compared to a decrease of 42,430,805.71 in the previous year[22]. - The ending balance of cash and cash equivalents was 177,123,351.40, up from 141,004,035.98 in the same period last year[22]. - The total cash outflow from financing activities was 261,440.32, compared to 540,276.01 in the previous year[22]. - The net cash flow from financing activities was -261,440.32, reflecting a decrease from -540,276.01 year-over-year[22]. Operational Insights - The increase in net profit was primarily driven by higher revenue, changes in product structure due to market demand, and tax incentives[8]. - The company reported a significant increase in net profit despite a decline in cash flow from operating activities, attributed to the increase in accounts receivable[8]. - Research and development expenses increased to ¥6,614,118.01 in Q1 2024, up from ¥4,126,878.25 in Q1 2023, marking a 60.5% rise[16]. - The company reported a total investment income of ¥409,317.55 for Q1 2024, compared to ¥264,657.53 in Q1 2023, reflecting a 54.4% increase[16]. - The company experienced a credit impairment loss of ¥4,872,708.39 in Q1 2024, worsening from a loss of ¥3,731,412.09 in Q1 2023[17]. Changes in Financial Position - Cash and cash equivalents increased to RMB 208,088,578.20 from RMB 187,621,748.94, representing a growth of approximately 10.8%[12]. - Accounts receivable rose to RMB 223,911,817.08 from RMB 152,379,478.91, marking an increase of around 47.0%[12]. - Inventory levels increased to RMB 203,320,983.13 from RMB 197,140,192.30, showing a growth of about 3.0%[13]. - The total amount of accounts payable increased to RMB 160,410,164.21 from RMB 147,604,207.25, reflecting a rise of about 8.5%[14]. - The company has no significant changes in the shareholding structure or participation in financing activities during the reporting period[12].

| 证券代码：603976 | 证券简称：正川股份 | 公告编号：2024-012 | | --- | --- | --- | | 债券代码：113624 | 债券简称：正川转债 | | 重庆正川医药包装材料股份有限公司 关于为全资子公司提供担保额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、担保情况概述 （一）本次担保的基本情况 为满足公司全资子公司的运营和发展需要，保证全资子公司生产经营活动的 顺利开展，在确保运作规范和风险可控的前提下，公司拟为全资子公司正川永成 申请银行贷款提供总额不超过 10,000 万元人民币连带责任保证担保，并授权公 司管理层根据实际经营情况和银行要求在该担保额度范围内办理担保事宜，具体 以签订的担保合同约定为准。本次担保额度有效期为董事会审议通过之日起一年 内有效。 （二）本次担保履行的内部决策程序 1 被担保人名称：重庆正川医药包装材料股份有限公司（以下简称"公司"） 之全资子公司重庆正川永成医药材料有限公司（以下简称"正川永成"）。 本次担保金额及已实际为其提 ...

二、资质附件………………………………………………… 第 3—7 页 目 录 | | | 内部控制审计报告 天健审〔2024〕8-219 号 重庆正川医药包装材料股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了重庆正川医药包装材料股份有限公司（以下简称正川股份公司）2023 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》《企业内部控制应用指引》以及《企业内部 控制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是正川 股份公司董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发表 审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 第 4 页 共 7 页 | 繁体版 Engli ...

目 录 | 一、审计报告……………………………………………………… 第 1—6 | | 页 | | | | --- | --- | --- | --- | --- | | 二、财务报表……………………………………………………… 第 7—14 | | 页 | | | | （一）合并资产负债表…………………………………………… | 第 | 7 页 | | | | （二）母公司资产负债表………………………………………… | 第 | 8 页 | | | | （三）合并利润表………………………………………………… | 第 | 页 | 9 | | | （四）母公司利润表………………………………………………第 | | 页 | | 10 | | （五）合并现金流量表……………………………………………第 | | 页 | | 11 | | （六）母公司现金流量表…………………………………………第 | | 页 | | 12 | | （七）合并所有者权益变动表……………………………………第 | | 页 | | 13 | | （八）母公司所有者权益变动表…………………………………第 | | 页 | | 14 | | | | 四、资质附 ...

关于重庆正川医药包装材料股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：重庆正川医药包装材料股份有限公司 审计单位：天健会计师事务所（特殊普通合伙） 联系电话：023-88868805 | | | 天健审〔2024〕8-220 号 | 一、非经营性资金占用及其他关联资金往来情况的专项 | | --- | | 审计说明 … | | 二、非经营性资金占用及其他关联资金往来情况汇总表 …………… 第3页 | | 三、资质附件 第 4-8 页 | 您可使用手机"扫一扫"成进入"注册会计师行业规资申计报"是否良兵有执业进中可的会计师事务 "您可使用手机"扫一扫"成进入"注册会计师行业统一监管平台（http://www.inform.com/new.php?title= 非经营性资金占用及其他关联资金往来情况的 专项审计说明 重庆正川医药包装材料股份有限公司全体股东: 我们接受委托,审计了重庆正川医药包装材料股份有限公司(以下简称正川 股份公司)2023年度财务报表,包括2023年12月31日的合并及母公司资产负 债表,2023年度的合并及母公 ...

重要内容提示： | | | 重庆正川医药包装材料股份有限公司 关于续聘公司 2024 年度审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙）（以下 简称"天健会计师事务所"） 一、拟聘任会计师事务所的基本情况 （一）机构信息 1.基本信息 | 事务所名称 | 天健会计师事务所（特殊普通合伙） | | | | | | --- | --- | --- | --- | --- | --- | | 成立日期 2011 | 年 7 月 18 日 | 组织形式 特殊普通合伙 | | | | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 | 128 | 号 | | | | 首席合伙人 王国海 | | 上年末合伙人数量 人 | | 238 | | | 上年末执业人 | 注册会计师 | | | 2,272 | 人 | | 员数量 | | 签署过证券服务业务审计报告的注册会计师 人 | | 836 | | | 2023 年（经审 | 业务收入总额 | 34.83 | 亿 ...

| | | 重庆正川医药包装材料股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和上 海证券交易所印发的《上海证券交易所上市公司自律监管指引第 1 号——规范运 作（2023 年 12 月修订）》（上证发〔2023〕193 号）等相关法律法规的规定，重 庆正川医药包装材料股份有限公司（以下简称"公司"或"正川股份"）对 2023 年年度募集资金的存放与实际使用情况进行专项报告如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准重庆正川医药包装材料股份有限公 司公开发行可转换公司债券的批复》（证监许可〔2021〕198 号），公司由主承销 商申万宏源证券承销保荐有限责任公司采用余额包销方式，向社会公众公开发行 可转换公司债券 4,050,000 张，每张面值为人 ...

Financial Performance - In 2023, the company achieved a net profit attributable to shareholders of CNY 40,267,655.57, a decrease of 37.83% compared to CNY 64,770,597.06 in 2022[6] - The operating revenue for 2023 was CNY 900,648,636.74, representing a year-on-year increase of 13.12% from CNY 796,198,292.56 in 2022[26] - Basic earnings per share decreased by 37.21% to CNY 0.27 in 2023 from CNY 0.43 in 2022[27] - Diluted earnings per share also fell by 37.21% to CNY 0.27 in 2023 compared to CNY 0.43 in 2022[27] - The weighted average return on equity dropped to 3.36% in 2023, down 2.15 percentage points from 5.51% in 2022[27] - The net profit attributable to shareholders for Q1 2023 was CNY 12,994,745.54, while Q2 was CNY 17,567,409.37, Q3 was CNY 5,148,828.22, and Q4 was CNY 4,556,672.44[29] - The company achieved operating revenue of 900.65 million yuan, an increase of 13.12% compared to the same period last year, with a net profit attributable to shareholders of 40.27 million yuan[37] Cash Flow and Assets - The net cash flow from operating activities reached CNY 194,196,180.49, a significant increase of 405.37% compared to CNY 38,426,207.67 in 2022[26] - The company's total assets as of the end of 2023 were CNY 2,042,882,148.49, reflecting a 1.75% increase from CNY 2,007,671,013.67 at the end of 2022[26] - The net assets attributable to shareholders increased by 2.64% to CNY 1,215,516,925.16 at the end of 2023, compared to CNY 1,184,205,802.31 at the end of 2022[26] - The cash and cash equivalents at the end of the period were CNY 30,370,475.86, fully restricted due to bank guarantees[74] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 2 per 10 shares, totaling CNY 30,240,407.80, which is 75.10% of the net profit attributable to shareholders for 2023[7] - The company does not plan to issue bonus shares or convert capital reserves into share capital this year[7] - The cash dividend distribution represents 75.10% of the net profit attributable to ordinary shareholders in the consolidated financial statements[131] Market and Growth Strategies - The company is focusing on expanding its market presence and enhancing product development strategies to drive future growth[36] - The company expanded its market presence in borosilicate products, adding nearly 100 new customers and positioning itself for growth in the next 2-3 years[37] - The company maintained stable sales growth in the soda-lime glass tube market, ensuring production and sales growth while solidifying its market position[38] - Significant progress was made in the market layout for pre-filled syringes and cartridge bottles, with successful collaborations with well-known pharmaceutical companies[38] - The company is actively participating in consistency evaluations and strategic collaborations with major pharmaceutical companies to capture market opportunities[43] Research and Development - The total R&D expenditure for the period was CNY 45,277,932.46, accounting for 5.03% of the operating revenue[67] - The number of R&D personnel is 258, representing 14.49% of the total workforce[68] - The company holds 47 patents, including 8 invention patents, reflecting its strong commitment to R&D in pharmaceutical glass packaging[52] Operational Efficiency and Technology - The company focused on equipment and technology upgrades, enhancing production efficiency and ensuring stable operations to meet diverse customer needs[39] - The company has implemented full-process automation in production, achieving 100% automation in bottle manufacturing, which significantly improves product quality[52] - The company has established a highly integrated production system for "tube-drawing, bottle-making, and cap-making," ensuring product quality and meeting personalized customer needs[44] Environmental and Sustainability Initiatives - The company invested 1,532.66 million CNY in environmental protection during the reporting period[136] - The company has constructed a wastewater treatment facility and has effective pollution control measures in place[140] - The company has implemented a technical transformation of one furnace to adopt full oxygen combustion technology, reducing energy consumption and carbon emissions[144] - The company is classified as a key pollutant discharge unit and has reported that all pollutant emissions are within the regulatory standards[137] Governance and Compliance - The company has established a compensation and performance evaluation committee to oversee the remuneration plans for directors and senior management, ensuring alignment with industry standards and company performance[105] - The company has independent directors serving in various capacities, enhancing governance and oversight[104] - The company has not faced any penalties from securities regulatory agencies in the past three years, indicating compliance with regulations[108] - The company has not reported any violations of commitments regarding related party transactions during the reporting period[161] Risks and Challenges - The company has disclosed potential risks related to future development strategies in the report[11] - The company faces potential risks from increasing regulatory standards for pharmaceutical packaging materials in China[88] - The company acknowledges the risk of quality issues in downstream pharmaceutical products affecting its sales and operations[89] - The company is dependent on the pharmaceutical industry's performance, which could impact its operational results if the industry experiences a downturn[89] Employee and Management Information - The company has a total of 1,781 employees, with 1,018 in the parent company and 763 in major subsidiaries[121] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 4.6493 million yuan[106] - The company has implemented a training plan for employees, including both internal and external training programs[123] Financial Management and Investments - The company has approved the use of up to 60,000,000 RMB of idle raised funds and 25,000,000 RMB of idle self-owned funds for cash management, with a maximum single-day investment not exceeding these limits[171] - The company has engaged in various bank wealth management products, with a total investment of 50,000,000 RMB from raised funds and 250,000,000 RMB from self-owned funds, all of which have been redeemed on time[172] - The company has committed to a new investment of 50,000,000 RMB in wealth management products, expecting a return of 404,178.08 RMB[174]